“They were quite clear that they are presenting the data to the FDA on 6/15 no matter where they are in the trial and that they are not going any further in getting more patients beyond that date, for the M2M trial.”

This is not exactly what was said yesterday and not exactly what is happening. CYDY is unblinding the M2M trial on the 15th of June, at which point any patient that needs to finish their two weeks will do so. Once the data is back from the final patient(s), and the entire data has been analyzed, CYDY will then send the data to the FDA and I’m assuming PR it as well. It may not be until mid-late July when we as investors see the data, and maybe even into August for an FDA decision and/or guidance.